0 89

Cited 0 times in

The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)

Authors
 Jae-Cheol Jo  ;  Ho Sup Lee  ;  Kihyun Kim  ;  Je-Jung Lee  ;  Sung-Soo Yoon  ;  Soo-Mee Bang  ;  Jin Seok Kim  ;  Hyeon-Seok Eom  ;  Dok Hyun Yoon  ;  Yoojin Lee  ;  Ho-Jin Shin  ;  Yong Park  ;  Won Sik Lee  ;  Young Rok Do  ;  Yeung-Chul Mun  ;  Mark Hong Lee  ;  Hyo Jung Kim  ;  Sung-Hyun Kim  ;  Min Kyoung Kim  ;  Sung-Nam Lim  ;  Su-Hee Cho  ;  Seong Kyu Park  ;  Jun Ho Yi  ;  Jae Hoon Lee  ;  Jinmi Kim  ;  Chang-Ki Min 
Citation
 ANNALS OF HEMATOLOGY, Vol.99(2) : 309-319, 2020-02 
Journal Title
ANNALS OF HEMATOLOGY
ISSN
 0939-5555 
Issue Date
2020-02
MeSH
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols / administration & dosage* ; Dexamethasone / administration & dosage ; Disease-Free Survival ; Female ; Humans ; Lenalidomide / administration & dosage ; Male ; Middle Aged ; Multiple Myeloma / drug therapy* ; Multiple Myeloma / mortality* ; Recurrence ; Republic of Korea / epidemiology ; Survival Rate
Keywords
Multiple myeloma ; Lenalidomide plus dexamethasone ; Effectiveness ; Survival ; Real-world evidence
Abstract
Although lenalidomide plus dexamethasone (RD) is a therapeutic option for relapsed/refractory multiple myeloma (RRMM), limited real-world clinical data exist. The purpose of this study was to estimate efficacy and safety of RD in RRMM patients of the clinical practice. Data from patients at 25 university hospitals in South Korea between October 2009 and December 2016 were collected retrospectively. We report the effectiveness and safety of RD in 546 RRMM patients in routine clinical practice in South Korea. Patients (median age, 65 years) typically received median 7 cycles of RD, and 184 (33.7%) patients were treated with 10 or more cycles of RD. Patients with renal impairment (CLCr < 40 mL/min; 10.4%), comorbid conditions (>= 2; 12.0%), and poor performance status (>= 2; 25.1%) were included. The overall response rate was 64.2%: complete response (13.1%), very good partial response (VGPR 19.9%). With median follow-up duration of 18.6 months, median PFS and OS were 11.2 months and 25.2 months, respectively. In multivariate analysis, less than 2 comorbid conditions, normal LDH, failed one chemotherapy prior to RD, and >= 10 cycles of RD therapy had significantly prolonged PFS (P = 0.007, P = 0.011, P = 0.007, and P < 0.001, respectively). Adverse events were acceptable. RD is effective and safe in real-life clinical practice, including patients with comorbidities. RD is an effective and safe treatment in a real clinical setting which includes patients with comorbidities. Early and continual use of RD treatment may improve RRMM survival outcomes.
Full Text
https://link.springer.com/article/10.1007/s00277-019-03904-7
DOI
10.1007/s00277-019-03904-7
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190257
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links